Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tetanus booster Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

NCT01732198
View directory record Official record
Conditions
Infectious Disease
Interventions
NU300, ActHIB, Prevnar 13
Biological
Lead sponsor
Nuron Biotech Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oakland, California • Bardstown, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 25, 2026, 12:59 PM EDT
Terminated Phase 1 Interventional

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

NCT00369291
View directory record Official record
Conditions
Germ Cell Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
keyhole limpet hemocyanin, tetanus toxoid
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT02465268
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions
pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
CMVpp65-A*0201 peptide vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2009 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 25, 2026, 12:59 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

NCT00345683
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,021 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 25, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 25, 2026, 12:59 PM EDT